Biomerica (BMRA) Competitors $3.24 +0.01 (+0.19%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. ESLA, BDRX, RANI, EYEN, MRNS, DYAI, KALA, ALLK, MAAQ, and ENLVShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Rani Therapeutics (RANI), Eyenovia (EYEN), Marinus Pharmaceuticals (MRNS), Dyadic International (DYAI), KALA BIO (KALA), Allakos (ALLK), Mana Capital Acquisition (MAAQ), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Estrella Immunopharma Biodexa Pharmaceuticals Rani Therapeutics Eyenovia Marinus Pharmaceuticals Dyadic International KALA BIO Allakos Mana Capital Acquisition Enlivex Therapeutics Biomerica (NASDAQ:BMRA) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Is BMRA or ESLA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-85.42% -85.90% -61.06% Estrella Immunopharma N/A -1,132.38%-273.91% Which has preferable earnings and valuation, BMRA or ESLA? Biomerica has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.53-$5.98M-$2.32-1.39Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.54 Do insiders and institutionals have more ownership in BMRA or ESLA? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate BMRA or ESLA? Estrella Immunopharma has a consensus target price of $16.00, suggesting a potential upside of 1,637.24%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to BMRA or ESLA? In the previous week, Biomerica had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Biomerica and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Biomerica's score of 0.56 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment Biomerica Positive Estrella Immunopharma Very Positive Which has more volatility and risk, BMRA or ESLA? Biomerica has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. SummaryEstrella Immunopharma beats Biomerica on 8 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.25M$2.43B$5.50B$9.00BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-1.398.8826.5720.02Price / Sales1.53672.33415.46120.95Price / CashN/A151.5836.1356.90Price / Book1.034.618.065.50Net Income-$5.98M$31.16M$3.15B$248.50M7 Day Performance1.13%0.51%1.72%2.61%1 Month Performance1.76%7.63%3.92%5.42%1 Year Performance-9.85%1.44%35.02%20.76% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.4506 of 5 stars$3.24+0.2%N/A-9.3%$8.25M$5.41M-1.3960News CoverageNegative NewsESLAEstrella Immunopharma2.4974 of 5 stars$0.96+9.0%$16.00+1,566.7%-19.2%$31.86MN/A-3.69N/APositive NewsGap UpBDRXBiodexa Pharmaceuticals0.5579 of 5 stars$0.87-0.6%N/AN/A$31.79M$470K0.0020Gap DownRANIRani Therapeutics2.2325 of 5 stars$0.51-6.9%$7.33+1,327.0%-86.3%$31.73M$1.03M-0.52110Positive NewsEYENEyenovia1.024 of 5 stars$10.38-4.6%$2.00-80.7%-73.3%$31.36M$60K-0.1840News CoverageHigh Trading VolumeMRNSMarinus Pharmaceuticals2.2975 of 5 stars$0.55-0.2%$3.92+613.3%-53.9%$30.32M$30.99M-0.22110DYAIDyadic International2.6223 of 5 stars$0.99-0.9%$6.00+506.1%-35.2%$30.06M$3.49M-4.957News CoverageKALAKALA BIO3.5839 of 5 stars$4.76+3.0%$13.50+183.6%-24.7%$29.81M$3.89M-0.5830ALLKAllakos2.8314 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190MAAQMana Capital AcquisitionN/A$3.61+9.4%N/A+556.4%$29.33MN/A0.001Gap UpHigh Trading VolumeENLVEnlivex Therapeutics3.3429 of 5 stars$1.12-6.7%$10.00+792.9%-14.4%$28.38MN/A-1.7070 Related Companies and Tools Related Companies Estrella Immunopharma Alternatives Biodexa Pharmaceuticals Alternatives Rani Therapeutics Alternatives Eyenovia Alternatives Marinus Pharmaceuticals Alternatives Dyadic International Alternatives KALA BIO Alternatives Allakos Alternatives Mana Capital Acquisition Alternatives Enlivex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
